Abevmy 400 mg/16 ml, Konzentrat zur Herstellung einer Infusionslösung

7680702610023 CH-70261 Konzentrat

Associated product:

ABEVMY 400 mg/16 ml conc 100 mg flac perf 1 pce

No image available

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Konzentrat
Galenic group
Tinkturen/Desinfektion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
01/03/2026
Summary of Product Characteristics
Français
01/03/2026
Summary of Product Characteristics
Italien
01/03/2026

Detailed composition

Substance Quantity Type Category
bevacizumabum
400.0 MG Substance Wirkstoff (Principe actif)
trehalosum dihydricum
- Substance HNIDK
natrii dihydrogenophosphas dihydricus
- Substance HNIDK
dinatrii phosphas
- Substance HNIDK
polysorbatum 20
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
acidum phosphoricum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
17.9 MG Substance HBESI

Reimbursement information

Public price
CHF 924.60
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/03/2026

Authorization holder

Medius AG

4132 Muttenz

Authorization information

Swissmedic authorization number
70261
Drug name
Abevmy, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOINF
ATC Code
L01FG01
Authorization status
Z
Dispensing category
A
First authorization
03/11/2025
Authorization expiration date
02/11/2030
IT Number
07.16.1.
Domain
Human medicine
Field of application
Onkologikum

Package details

Description (FR)
ABEVMY 400 mg/16 ml conc 100 mg flac perf 1 pce
Description (DE)
ABEVMY 400 mg/16 ml Konz Inf 400 mg Durchstf 1 Stk
Market launch
01/03/2026
Narcotic (BTM)
No

Other package sizes (1)

ABEVMY 100 mg/4 ml conc inf 100 mg flac perf 1 pce
1 DUR
GTIN: 7680702610016
View
Buy us a coffee Explore the data